After $4B Takeda deal, Nimbus lays out ‘grand’ hopes for its next-gen immunotherapy drug
ImmunotherapyClinical StudyClinical Result
Just over a year ago, Nimbus Therapeutics closed one of the biggest single-drug deals in biotech, selling its TYK2 inhibitorTYK2 inhibitor to Takeda for $4 billion upfront. Now, CEO Jeb Keiper is planning the company’s next act.
On Thursday, Nimbus shared updated data for NDI-101150, the biotech’s sole clinical-stage drug being tested in cancer patients with advanced solid tumors. In an interview with Endpoints News, Keiper said he’s “incredibly encouraged” by early results from the ongoing Phase 1/2 trial, which showed 5 of 30 patients (17%) with clinical benefit to its small molecule inhibiting the HPK1 protein.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.